Smith & Nephew plc Website

Smith & Nephew plc

LSE-SN.

Company Overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

  • Name

    Smith & Nephew plc

  • CEO

    Deepak S. Nath

  • Website

    www.smith-nephew.com

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    1856

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Smith & Nephew participates in the fast-growing sports medicine arena, thanks to its extensive arthroscopy portfolio.

  • A strong arthroscopy presence in ambulatory surgical centers leaves Smith & Nephew well positioned to expand its large-joint presence in that setting.

  • Smith & Nephew has been building out its presence in emerging markets. Considering the obstacles in developed markets that keep it from transforming into a top-tier player, S&N may enjoy greater upside in developing markets.

Bears Say

  • Smith & Nephew's attempted shift to the lower-cost Syncera distribution model in the US was disappointing, which leaves the firm in a tenuous competitive position for large-joint replacement in that market.

  • As orthopedic surgeons have displayed enthusiasm for the adoption of rival robots from Stryker and Zimmer Biomet, Smith & Nephew's smaller, hand-held robot may be seen as a niche product better suited for ASCs.

  • Turnover in the C-suite coincided with the revelation of many operational deficiencies that need to be addressed to put the firm on the path to profitable growth.

Source: Morningstar Analysis - Nov 17, 2025

What's happening

Nov 13, 2025 - Dec 13, 2025

Smith & Nephew PLC Faces Mixed Analyst Sentiment Amid Strategic Updates

  • Smith & Nephew PLC announced a trading profit margin target of at least 19.5% for 2025 and free cash flow projections around $800 million.
  • The company set an underlying revenue growth target of 6%-7% for 2028, confirming it is on track with its existing goals.
  • Despite positive announcements, the stock faced mixed ratings from analysts that contributed to investor uncertainty.

Over the past month, Smith & Nephew PLC (SNN) experienced a decline of 2.5%, significantly underperforming compared to the S&P 500's slight dip of only 0.2%. This period was characterized by mixed analyst sentiments and strategic updates that influenced market perceptions. On December 8, SNN saw a positive movement of 2.1% following announcements regarding its financial expectations for upcoming years.

Despite this bullish sentiment, varying analyst ratings throughout the month contributed to uncertainty among investors. Wall Street Zen downgraded SNN from "strong-buy" to "buy," while Royal Bank of Canada maintained an "outperform" rating, indicating some confidence in the stock's potential despite overall caution in market sentiment toward SNN’s performance trajectory.

Bearish factors also emerged during November when significant partnerships within the uranium sector involving Skyharbour Resources Ltd diverted investor attention away from SNN's core operations in medical devices and wound management. Additionally, on November 17th, there was a modest gain of half a percent attributed to institutional interest and solid financial ratios like a current ratio of 2.51; however, this did not translate into sustained upward momentum.

Overall market conditions were challenging for healthcare stocks during this timeframe; Smith & Nephew PLC underperformed relative to both its sector and broader indices such as the Health Care (XLV) sector by -3.3%. The combination of fluctuating analyst ratings alongside strategic updates created an environment where optimism could not fully counterbalance concerns over competitive pressures and broader economic indicators impacting investor confidence across sectors.

Smith & Nephew PLC underperformed relative to the S&P by -2.3%.

LSE:SN.